# Kidney Biopsy Interpretation

Light Microscopy, Immunofluorescence & Electron Microscopy: Pattern Recognition for Glomerular Disease

Light Microscopy Immunofluorescence Electron Microscopy Pattern-to-Disease

### Quick Navigation

[Specimen Adequacy](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/biopsy-interpretation.html#adequacy) [Light Microscopy](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/biopsy-interpretation.html#light-microscopy) [Immunofluorescence](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/biopsy-interpretation.html#immunofluorescence) [Electron Microscopy](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/biopsy-interpretation.html#electron-microscopy) [Pattern-to-Disease Table](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/biopsy-interpretation.html#pattern-disease) [Special Stains](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/biopsy-interpretation.html#special-stains)

## Specimen Adequacy

A kidney biopsy must contain sufficient cortical tissue to allow confident diagnosis. Inadequate samples may lead to missed focal diseases (e.g., FSGS) or underestimate disease severity.

### Minimum for Diagnosis

8–10 glomeruli

Minimum glomerular count for reliable histologic diagnosis

### Ideal Sample

20+ glomeruli

Especially important for focal diseases like FSGS

### Cores Required

2–3 cores

Each core 1–2 cm length; 16-gauge needle standard

**Clinical Pearl:** FSGS lesions are focal (not all glomeruli affected) and segmental (not the entire glomerulus). With only 5 glomeruli, there is a significant chance of missing FSGS. Statistical modeling shows that ≥25 glomeruli are needed to exclude FSGS with 90% confidence if the true prevalence of affected glomeruli is 10%.

### Tissue Distribution Across Studies

| Study | Fixative/Medium | Purpose |
|----|----|----|
| **Light Microscopy** | Formalin-fixed, paraffin-embedded | Structural patterns, cellularity, sclerosis, fibrosis |
| **Immunofluorescence** | Snap-frozen (OCT medium) | Immune deposits (IgG, IgA, IgM, C3, C1q, kappa, lambda) |
| **Electron Microscopy** | Glutaraldehyde-fixed | Deposit location, foot process effacement, basement membrane |

## Light Microscopy Patterns

### Proliferative Patterns

#### Mesangial Proliferation

**Definition:** Increased mesangial cells (\>3 per mesangial area) and/or matrix expansion

**Key diseases:**

- IgA nephropathy
- Early lupus nephritis (Class II)
- Diabetic nephropathy

#### Endocapillary Proliferation

**Definition:** Increased cellularity within glomerular capillary lumina (endothelial cells, monocytes, neutrophils)

**Key diseases:**

- Post-infectious GN (diffuse)
- Lupus nephritis Class III/IV
- MPGN
- IgA nephropathy (with activity)

#### Extracapillary Proliferation (Crescents)

**Definition:** Proliferation in Bowman’s space forming crescents; indicates severe injury with capsule rupture

**Key diseases:**

- ANCA vasculitis (pauci-immune)
- Anti-GBM disease (Goodpasture)
- Lupus nephritis Class IV with crescents
- Severe IgA nephropathy

### Crescent Classification — Prognostic Significance

#### Cellular Crescent

Predominantly cells (epithelial cells, macrophages)

**Prognosis:** Potentially reversible with immunosuppression

→

#### Fibrocellular Crescent

Mix of cells and fibrosis

**Prognosis:** Partially reversible; intermediate prognosis

→

#### Fibrous Crescent

Predominantly collagen/fibrosis

**Prognosis:** Irreversible; represents end-stage glomerular scarring

### Sclerosis Patterns

| Pattern | Definition | Clinical Significance |
|----|----|----|
| **Segmental Sclerosis** | Sclerosis involving part of the glomerular tuft | FSGS (primary or secondary); perihilar variant suggests adaptive FSGS |
| **Global Sclerosis** | Entire glomerulus replaced by scar tissue | End-stage of any glomerular injury; \>50% globally sclerosed = poor prognosis for recovery |
| **Nodular Sclerosis** | Kimmelstiel-Wilson nodules (mesangial nodular expansion) | Pathognomonic for diabetic nephropathy; also seen in LCDD and amyloid |

### Necrosis

**Fibrinoid necrosis** of capillary loops indicates severe, active injury. Characteristic of:

- ANCA vasculitis (segmental necrosis)
- Anti-GBM disease
- Thrombotic microangiopathy (TMA)
- Malignant hypertension

### Interstitial Fibrosis & Tubular Atrophy (IFTA) — Chronicity Index

| Grade | % Cortex Affected | Significance |
|----|----|----|
| **Mild (Grade 1)** | \<25% | Early chronic changes; may still respond to therapy |
| **Moderate (Grade 2)** | 25–50% | Significant chronic damage; partial response expected |
| **Severe (Grade 3)** | \>50% | Advanced chronicity; unlikely to recover; may be futile to treat with immunosuppression |

**Clinical Pearl:** IFTA is the single best histologic predictor of long-term renal prognosis, regardless of the primary disease. Advanced IFTA (\>50%) generally indicates irreversible damage and should prompt discussion about CKD management rather than aggressive immunosuppression.

## Immunofluorescence (IF) Patterns

IF identifies the type and distribution of immune deposits. The staining pattern is the single most important diagnostic clue for classifying glomerulonephritis.

### Key IF Patterns

#### LINEAR IgG Staining

**Pattern:** Smooth, continuous IgG along the GBM

**Disease:** Anti-GBM disease (Goodpasture syndrome)

**Mechanism:** Antibodies directed against the alpha-3 chain of type IV collagen in the GBM

**Also seen:** Diabetic nephropathy (non-specific trapping; no clinical significance)

#### GRANULAR Staining

**Pattern:** Lumpy-bumpy, discontinuous deposits along capillary walls and/or mesangium

**Diseases:**

- Membranous nephropathy (granular IgG, C3 along capillary walls)
- Post-infectious GN (granular IgG, C3 — "starry sky")
- MPGN
- Lupus nephritis

#### FULL HOUSE Staining

**Pattern:** IgG, IgA, IgM, C3, *and* C1q all positive

**Disease:** Lupus nephritis (virtually pathognomonic)

**Significance:** C1q positivity is particularly characteristic of SLE; helps distinguish from other immune complex diseases

#### PAUCI-IMMUNE (Negative IF)

**Pattern:** Little or no immunoglobulin or complement staining

**Diseases:**

- ANCA-associated vasculitis (GPA, MPA, EGPA)

**Significance:** Crescentic GN with negative IF strongly suggests ANCA vasculitis; check serum ANCA (MPO, PR3)

#### IgA DOMINANT Staining

**Pattern:** IgA as the dominant or co-dominant immunoglobulin, primarily mesangial

**Diseases:**

- IgA nephropathy (Berger disease)
- IgA vasculitis (Henoch-Schönlein purpura) nephritis

**Note:** May also have C3 and IgG co-staining; C1q is typically absent (classical pathway not activated)

#### Light Chain Restriction

**Pattern:** Monoclonal kappa OR lambda staining (not both)

**Diseases:**

- Light chain deposition disease (LCDD)
- AL amyloidosis
- Proliferative GN with monoclonal Ig deposits (PGNMID)

**Significance:** Monoclonal restriction = paraprotein-related disease; search for underlying hematologic malignancy

## Electron Microscopy: Deposit Location

EM localizes immune deposits relative to the glomerular basement membrane (GBM) and evaluates podocyte foot processes. Deposit location is the single most specific finding for disease classification.

### Deposit Locations and Disease Correlation

Subepithelial

Between GBM and podocytes

------------------------------------------------------------------------

- **Membranous nephropathy** (diffuse)
- Post-infectious GN ("humps")
- Lupus Class V

Subendothelial

Between GBM and endothelium

------------------------------------------------------------------------

- **Lupus nephritis Class III/IV**
- MPGN Type I
- **Wire-loop lesions** (massive subendothelial deposits in lupus)

Mesangial

Within the mesangium

------------------------------------------------------------------------

- **IgA nephropathy**
- Lupus Class I/II
- Early diabetic nephropathy

Intramembranous

Within the GBM itself

------------------------------------------------------------------------

- **Dense deposit disease** (C3 GN / MPGN Type II)
- Ribbon-like dense transformation of the GBM

### Foot Process Effacement

#### Diffuse Effacement (\>80%)

Indicates podocytopathy with massive proteinuria

- **Minimal Change Disease:** Diffuse effacement with NO deposits, NO proliferation, NO sclerosis
- **Primary FSGS:** Diffuse effacement with segmental sclerosis

#### Focal/Segmental Effacement

Seen overlying areas of immune deposits or sclerosis

- Secondary FSGS (adaptive): effacement 30–60%
- Membranous nephropathy: effacement over deposits
- Immune complex GN: focal effacement near deposits

**High-Yield Distinction — MCD vs. FSGS on EM:** In MCD, foot process effacement is diffuse (\>80%) but the biopsy otherwise appears normal (no immune deposits, no sclerosis). In primary FSGS, diffuse effacement is present along with segmental sclerosis on LM. In secondary/adaptive FSGS, effacement is typically only 30–60% and limited to areas near sclerotic segments.

### Wire-Loop Lesions (Lupus Nephritis)

**Wire-loop lesions** represent massive subendothelial immune complex deposits that thicken the capillary wall, making it appear rigid and refractile on LM (resembling a wire loop).

- **Virtually pathognomonic for:** Lupus nephritis Class IV (diffuse proliferative)
- **On EM:** Massive electron-dense subendothelial deposits
- **Clinical significance:** Indicates severe, active disease requiring aggressive immunosuppression

## Comprehensive Pattern-to-Disease Correlation

| Disease | Light Microscopy | Immunofluorescence | Electron Microscopy | Key Diagnostic Feature |
|----|----|----|----|----|
| **Minimal Change Disease** | Normal glomeruli | Negative | Diffuse foot process effacement; no deposits | Normal LM + diffuse FPE on EM |
| **FSGS (Primary)** | Segmental sclerosis (may be focal) | Nonspecific IgM/C3 trapping in sclerotic areas | Diffuse FPE (\>80%) | Segmental sclerosis + diffuse FPE |
| **Membranous Nephropathy** | GBM thickening, spikes on silver stain | Granular IgG, C3 along capillary walls | Subepithelial deposits with GBM reaction (stages I–IV) | Subepithelial deposits; anti-PLA2R antibody |
| **IgA Nephropathy** | Mesangial proliferation (variable) | Dominant IgA in mesangium (±C3, IgG) | Mesangial electron-dense deposits | Dominant mesangial IgA on IF |
| **Post-Infectious GN** | Diffuse endocapillary proliferation; neutrophil infiltration | Granular IgG, C3 ("starry sky") | Subepithelial "humps" | Subepithelial humps + starry sky IF |
| **Lupus Nephritis III/IV** | Endocapillary proliferation, crescents, wire-loop lesions | "Full house" (IgG, IgA, IgM, C3, C1q) | Subendothelial deposits (tubuloreticular inclusions) | Full house IF + subendothelial deposits |
| **Lupus Nephritis V** | GBM thickening (mimics membranous) | Full house | Subepithelial deposits | Membranous pattern + full house IF |
| **Anti-GBM Disease** | Crescentic GN, fibrinoid necrosis | Linear IgG along GBM | No electron-dense deposits | Linear IgG + crescents |
| **ANCA Vasculitis** | Focal segmental necrosis, crescents | Pauci-immune (negative or scant) | No or scant immune deposits | Crescentic GN + pauci-immune IF |
| **MPGN Type I** | Mesangial interposition, "tram-tracking" of GBM | Granular C3, IgG; variable | Subendothelial deposits, mesangial interposition | Tram-tracking + subendothelial deposits |
| **Dense Deposit Disease** | MPGN pattern or mesangial proliferative | C3 dominant (C3 glomerulopathy) | Intramembranous dense osmiophilic transformation | Ribbon-like intramembranous dense deposits |
| **Diabetic Nephropathy** | Kimmelstiel-Wilson nodules, GBM thickening, mesangial expansion | Linear IgG (non-specific trapping), albumin | GBM thickening, mesangial expansion | Nodular mesangial sclerosis (clinical context) |
| **Amyloidosis (AL/AA)** | Amorphous eosinophilic deposits; Congo red positive with apple-green birefringence | Lambda or kappa restriction (AL) or negative (AA) | Non-branching fibrils 8–12 nm | Congo red birefringence + 8–12 nm fibrils |
| **Fibrillary GN** | MPGN or mesangial pattern | Polyclonal IgG, C3; DNAJB9 positive | Randomly arranged fibrils 16–24 nm | Fibrils larger than amyloid (16–24 nm); Congo red negative |

## Special Stains and Techniques

| Stain | Highlights | Clinical Use |
|----|----|----|
| **Congo Red** | Amyloid fibrils; apple-green birefringence under polarized light | Diagnosis of amyloidosis (AL, AA, ALECT2). Must examine under polarized light to confirm birefringence. |
| **Jones Methenamine Silver (JMS)** | Basement membranes; GBM spikes and double contours | Membranous nephropathy (spikes), MPGN (tram-tracking), GBM abnormalities |
| **PAS (Periodic Acid-Schiff)** | Glycoproteins, basement membranes, mesangial matrix | GBM thickening (diabetic, membranous), mesangial expansion, tubular basement membranes |
| **Trichrome (Masson)** | Collagen (blue/green), immune deposits (red/fuchsinophilic) | Quantify interstitial fibrosis; identify fuchsinophilic deposits (immune complex, fibrin) |
| **H&E** | General architecture, cellularity | Initial assessment of glomerular, tubular, interstitial, and vascular compartments |
| **Thioflavin T** | Amyloid (fluorescent) | More sensitive than Congo red for small amyloid deposits |

**Congo Red — High-Yield:** Amyloid deposits appear salmon-pink on H&E and show **apple-green birefringence under polarized light** after Congo red staining. This is pathognomonic for amyloidosis. Always request Congo red when amyloid is suspected (nephrotic syndrome in older patient, cardiac involvement, neuropathy, hepatomegaly).

## References

1.  Sethi S, Haas M, Markowitz GS, et al. Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. *J Am Soc Nephrol*. 2016;27(5):1278-1287. [PubMed](https://pubmed.ncbi.nlm.nih.gov/26567243/)
2.  Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the ISN/RPS classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. *Kidney Int*. 2018;93(4):789-796. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29459092/)
3.  Trimarchi H, Barratt J, Cattran DC, et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. *Kidney Int*. 2017;91(5):1014-1021. [PubMed: 28341274](https://pubmed.ncbi.nlm.nih.gov/28341274/)
4.  D'Agati VD, Fogo AB, Bruijn JA, et al. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. *Am J Kidney Dis*. 2004;43(2):368-382. [PubMed](https://pubmed.ncbi.nlm.nih.gov/14750104/)
5.  KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. *Kidney Int*. 2021;100(4S):S1-S276. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34556256/)
6.  Whittier WL, Korbet SM. Timing of complications in percutaneous renal biopsy. *J Am Soc Nephrol*. 2004;15(1):142-147. [PubMed](https://pubmed.ncbi.nlm.nih.gov/14694166/)
7.  Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. *J Am Soc Nephrol*. 2009;20(9):2055-2064. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19470674/)
8.  Nasr SH, Valeri AM, Cornell LD, et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. *Clin J Am Soc Nephrol*. 2011;6(4):775-784. [PubMed](https://pubmed.ncbi.nlm.nih.gov/21441134/)
9.  Corapi KM, Chen JLT, Balk EM, Gordon CE. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. *Am J Kidney Dis*. 2012;60(1):62-73. [PubMed](https://pubmed.ncbi.nlm.nih.gov/22537423/)

**Andrew Bland, MD, FACP, FAAP** \| University of Dubuque PA Program \| Urine Nephrology Now

© 2025 \| For educational purposes only

### Also on this topic

The same subject at other levels of depth.

- **Student handout:** [Kidney Biopsy: A Comprehensive Student Guide](https://urinenephrology.org/student-resources/procedures/kidney-biopsy-student-handout.html)
- **Patient handout:** [Kidney Biopsy: What to Expect](https://urinenephrology.org/patient-handouts/kidney-biopsy-what-to-expect.html)


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/biopsy-interpretation.html) · Markdown synchronized October 3, 2026.